{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T15:31:19Z","timestamp":1794324679065,"version":"4.9.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T00:00:00Z","timestamp":1741219200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-91734-1","type":"journal-article","created":{"date-parts":[[2025,3,6]],"date-time":"2025-03-06T13:38:03Z","timestamp":1741268283000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["The gut microbiota during tamoxifen therapy in patients with breast cancer"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7010-7610","authenticated-orcid":false,"given":"Lars E.","family":"Hillege","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1961-7206","authenticated-orcid":false,"given":"David J. M.","family":"Barnett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4559-5488","authenticated-orcid":false,"given":"Janine","family":"Ziemons","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8713-9747","authenticated-orcid":false,"given":"Romy","family":"Aarnoutse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2578-1766","authenticated-orcid":false,"given":"Judith","family":"de Vos-Geelen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1880-8131","authenticated-orcid":false,"given":"Robin","family":"van Geel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0835-8651","authenticated-orcid":false,"given":"Maaike","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yvonne E. A.","family":"van Riet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeroen","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9146-5919","authenticated-orcid":false,"given":"John","family":"Penders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8328-1869","authenticated-orcid":false,"given":"Marjolein L.","family":"Smidt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,6]]},"reference":[{"issue":"7","key":"91734_CR1","doi-asserted-by":"publisher","first-page":"6834","DOI":"10.3390\/ijms24076834","volume":"24","author":"L Clusan","year":"2023","unstructured":"Clusan, L., Ferri\u00e8re, F., Flouriot, G. & Pakdel, F. A basic review on estrogen receptor signaling pathways in breast cancer. Int. J. Mol. Sci. 24(7), 6834 (2023).","journal-title":"Int. J. Mol. Sci."},{"issue":"3","key":"91734_CR2","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1016\/j.pharmthera.2013.05.005","volume":"139","author":"G Yang","year":"2013","unstructured":"Yang, G., Nowsheen, S., Aziz, K. & Georgakilas, A. G. Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs. Pharmacol. Ther. 139(3), 392\u2013404 (2013).","journal-title":"Pharmacol. Ther."},{"issue":"6","key":"91734_CR3","doi-asserted-by":"publisher","first-page":"523","DOI":"10.1080\/17512433.2019.1610390","volume":"12","author":"AB Sanchez-Spitman","year":"2019","unstructured":"Sanchez-Spitman, A. B. et al. Clinical pharmacokinetics and pharmacogenetics of tamoxifen and endoxifen. Expert. Rev. Clin. Pharmacol. 12(6), 523\u2013536 (2019).","journal-title":"Expert. Rev. Clin. Pharmacol."},{"issue":"9793","key":"91734_CR4","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0140-6736(11)60993-8","volume":"378","author":"C Davies","year":"2011","unstructured":"Davies, C. et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials. Lancet 378(9793), 771\u2013784 (2011).","journal-title":"Lancet"},{"issue":"13","key":"91734_CR5","doi-asserted-by":"publisher","first-page":"3164","DOI":"10.1158\/1078-0432.CCR-15-1470","volume":"22","author":"P Fox","year":"2016","unstructured":"Fox, P. et al. Dose Escalation of tamoxifen in patients with low endoxifen level: Evidence for therapeutic drug monitoring-the TADE study. Clin. Cancer Res. 22(13), 3164\u20133171 (2016).","journal-title":"Clin. Cancer Res."},{"issue":"1","key":"91734_CR6","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1007\/s10549-022-06643-y","volume":"195","author":"CL Braal","year":"2022","unstructured":"Braal, C. L. et al. Factors affecting inter-individual variability in endoxifen concentrations in patients with breast cancer: Results from the prospective TOTAM trial. Breast Cancer Res. Treat. 195(1), 65\u201374 (2022).","journal-title":"Breast Cancer Res. Treat."},{"issue":"3","key":"91734_CR7","doi-asserted-by":"publisher","first-page":"1107","DOI":"10.1007\/s10549-011-1893-4","volume":"132","author":"W Lorizio","year":"2012","unstructured":"Lorizio, W. et al. Clinical and biomarker predictors of side effects from tamoxifen. Breast Cancer Res. Treat. 132(3), 1107\u20131118 (2012).","journal-title":"Breast Cancer Res. Treat."},{"key":"91734_CR8","doi-asserted-by":"publisher","first-page":"1121471","DOI":"10.3389\/fonc.2023.1121471","volume":"13","author":"H Li","year":"2023","unstructured":"Li, H. et al. Potential risk of tamoxifen: Gut microbiota and inflammation in mice with breast cancer. Front. Oncol. 13, 1121471 (2023).","journal-title":"Front. Oncol."},{"issue":"7698","key":"91734_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1038\/nature25979","volume":"555","author":"L Maier","year":"2018","unstructured":"Maier, L. et al. Extensive impact of non-antibiotic drugs on human gut bacteria. Nature 555(7698), 623\u2013628 (2018).","journal-title":"Nature"},{"key":"91734_CR10","first-page":"139","volume":"179","author":"JL Pope","year":"2017","unstructured":"Pope, J. L., Tomkovich, S., Yang, Y. & Jobin, C. Microbiota as a mediator of cancer progression and therapy. Trans. Res. J. Lab. Clin. Med. 179, 139\u2013154 (2017).","journal-title":"Trans. Res. J. Lab. Clin. Med."},{"issue":"9","key":"91734_CR11","first-page":"560","volume":"9","author":"EM Quigley","year":"2013","unstructured":"Quigley, E. M. Gut bacteria in health and disease. Gastroenterol. Hepatol. 9(9), 560\u2013569 (2013).","journal-title":"Gastroenterol. Hepatol."},{"issue":"29","key":"91734_CR12","doi-asserted-by":"publisher","first-page":"8787","DOI":"10.3748\/wjg.v21.i29.8787","volume":"21","author":"SM Jandhyala","year":"2015","unstructured":"Jandhyala, S. M. et al. Role of the normal gut microbiota. World J. Gastroenterol. 21(29), 8787\u20138803 (2015).","journal-title":"World J. Gastroenterol."},{"issue":"6086","key":"91734_CR13","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1126\/science.1224396","volume":"336","author":"HJ Haiser","year":"2012","unstructured":"Haiser, H. J. & Turnbaugh, P. J. Is it time for a metagenomic basis of therapeutics?. Science 336(6086), 1253\u20131255 (2012).","journal-title":"Science"},{"issue":"1","key":"91734_CR14","doi-asserted-by":"publisher","first-page":"5595","DOI":"10.1038\/s41467-022-33299-5","volume":"13","author":"C Diot","year":"2022","unstructured":"Diot, C. et al. Bacterial diet modulates tamoxifen-induced death via host fatty acid metabolism. Nat. Commun. 13(1), 5595 (2022).","journal-title":"Nat. Commun."},{"issue":"17","key":"91734_CR15","doi-asserted-by":"publisher","first-page":"4145","DOI":"10.3390\/ijms20174145","volume":"20","author":"R Aarnoutse","year":"2019","unstructured":"Aarnoutse, R. et al. The clinical link between human intestinal microbiota and systemic cancer therapy. Int. J. Mol. Sci. 20(17), 4145 (2019).","journal-title":"Int. J. Mol. Sci."},{"issue":"1","key":"91734_CR16","doi-asserted-by":"publisher","first-page":"e0167924","DOI":"10.1128\/mbio.01679-24","volume":"16","author":"Y Alam","year":"2025","unstructured":"Alam, Y. et al. Variation in human gut microbiota impacts tamoxifen pharmacokinetics. mBio 16(1), e0167924 (2025).","journal-title":"mBio"},{"issue":"20","key":"91734_CR17","doi-asserted-by":"publisher","first-page":"2105","DOI":"10.1200\/JCO.2018.77.8738","volume":"36","author":"AC Wolff","year":"2018","unstructured":"Wolff, A. C. et al. Human epidermal growth factor receptor 2 testing in breast cancer: American society of clinical oncology\/college of american pathologists clinical practice guideline focused update. J. Clin. Oncol. 36(20), 2105\u20132122 (2018).","journal-title":"J. Clin. Oncol."},{"key":"91734_CR18","unstructured":"Richtlijnendatabase Borstkanker. In.: Federatie Medisch Specialisten (2024)."},{"issue":"8","key":"91734_CR19","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1093\/annonc\/mdz173","volume":"30","author":"F Cardoso","year":"2019","unstructured":"Cardoso, F. et al. Early breast cancer: ESMO clinical Practice Guidelines for diagnosis, treatment and follow-up\u2020. Ann. Oncol. 30(8), 1194\u20131220 (2019).","journal-title":"Ann. Oncol."},{"issue":"2","key":"91734_CR20","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1200\/JOP.18.00617","volume":"15","author":"HJ Burstein","year":"2019","unstructured":"Burstein, H. J., Lacchetti, C. & Griggs, J. J. Adjuvant endocrine therapy for women with hormone receptor-positive breast cancer: ASCO clinical practice guideline focused update. J. Oncol. Pract. 15(2), 106\u2013107 (2019).","journal-title":"J. Oncol. Pract."},{"issue":"1","key":"91734_CR21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1038\/s41523-022-00455-5","volume":"8","author":"R Aarnoutse","year":"2022","unstructured":"Aarnoutse, R. et al. Changes in intestinal microbiota in postmenopausal oestrogen receptor-positive breast cancer patients treated with (neo)adjuvant chemotherapy. NPJ Breast Cancer 8(1), 89 (2022).","journal-title":"NPJ Breast Cancer"},{"issue":"8","key":"91734_CR22","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1038\/ismej.2012.8","volume":"6","author":"JG Caporaso","year":"2012","unstructured":"Caporaso, J. G. et al. Ultra-high-throughput microbial community analysis on the Illumina HiSeq and MiSeq platforms. Isme J. 6(8), 1621\u20131624 (2012).","journal-title":"Isme J."},{"issue":"10","key":"91734_CR23","doi-asserted-by":"publisher","first-page":"1273","DOI":"10.1093\/ecco-jcc\/jjz049","volume":"13","author":"G Galazzo","year":"2019","unstructured":"Galazzo, G. et al. Faecal microbiota dynamics and their relation to disease course in crohn\u2019s disease. J. Crohns. Colitis 13(10), 1273\u20131282 (2019).","journal-title":"J. Crohns. Colitis"},{"issue":"1","key":"91734_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.14806\/ej.17.1.200","volume":"17","author":"M Martin","year":"2011","unstructured":"Martin, M. Cutadapt removes adapter sequences from high-throughput sequencing reads. EMBnet J. 17(1), 10\u201312 (2011).","journal-title":"EMBnet J."},{"issue":"7","key":"91734_CR25","doi-asserted-by":"publisher","first-page":"581","DOI":"10.1038\/nmeth.3869","volume":"13","author":"BJ Callahan","year":"2016","unstructured":"Callahan, B. J. et al. DADA2: High-resolution sample inference from Illumina amplicon data. Nat. Methods 13(7), 581\u2013583 (2016).","journal-title":"Nat. Methods"},{"issue":"Data base issue","key":"91734_CR26","first-page":"590","volume":"41","author":"C Quast","year":"2013","unstructured":"Quast, C. et al. The SILVA ribosomal RNA gene database project: Improved data processing and web-based tools. Nucleic Acids Res. 41(Data base issue), 590\u2013596 (2013).","journal-title":"Nucleic Acids Res."},{"key":"91734_CR27","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.jchromb.2019.01.001","volume":"1106\u20131107","author":"M van Nuland","year":"2019","unstructured":"van Nuland, M. et al. Development and validation of an UPLC-MS\/MS method for the therapeutic drug monitoring of oral anti-hormonal drugs in oncology. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 1106\u20131107, 26\u201334 (2019).","journal-title":"J. Chromatogr. B Analyt. Technol. Biomed. Life Sci."},{"key":"91734_CR28","unstructured":"R: A language and environment for statistical computing. (R Foundation for Statistical Computing, Vienna). https:\/\/www.R-project.org\/"},{"issue":"4","key":"91734_CR29","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0061217","volume":"8","author":"PJ McMurdie","year":"2013","unstructured":"McMurdie, P. J. & Holmes, S. phyloseq: An R package for reproducible interactive analysis and graphics of microbiome census data. PLoS One 8(4), e61217 (2013).","journal-title":"PLoS One"},{"key":"91734_CR30","unstructured":"psych: Procedures for Personality and Psychological Research, Northwestern University, Evanston, Illinois, USA. https:\/\/CRAN.R-project.org\/package=psychVersion=2.2.5."},{"issue":"1","key":"91734_CR31","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1111\/j.2517-6161.1995.tb02031.x","volume":"57","author":"Y Benjamini","year":"1995","unstructured":"Benjamini, Y. & Hochberg, Y. Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R. Stat. Soc. Series B (Methodological) 57(1), 289\u2013300 (1995).","journal-title":"J. R. Stat. Soc. Series B (Methodological)"},{"key":"91734_CR32","unstructured":"R package \u201ccorrplot\u201d: Visualization of a Correlation Matrix (Version 0.84) [https:\/\/github.com\/taiyun\/corrplot]"},{"key":"91734_CR33","unstructured":"vegan: Community Ecology Package. R package version 2.5-6. [https:\/\/CRAN.R-project.org\/package=vegan]"},{"key":"91734_CR34","unstructured":"microbiome R package [http:\/\/microbiome.github.io]"},{"key":"91734_CR35","volume-title":"dplyr: A Grammar of Data Manipulation","author":"H Wickham","year":"2022","unstructured":"Wickham, H., Fran\u00e7ois, R., Henry, L. & M\u00fcller, K. dplyr: A Grammar of Data Manipulation (R package version 1.0.9. In, 2022)."},{"key":"91734_CR36","doi-asserted-by":"publisher","DOI":"10.1007\/978-3-319-24277-4","volume-title":"ggplot2: Elegant Graphics for Data Analysis","author":"H Wickham","year":"2016","unstructured":"Wickham, H. ggplot2: Elegant Graphics for Data Analysis (Springer, 2016)."},{"issue":"63","key":"91734_CR37","doi-asserted-by":"publisher","first-page":"3201","DOI":"10.21105\/joss.03201","volume":"6","author":"D Barnett","year":"2021","unstructured":"Barnett, D., Arts, I. & Penders, J. microViz: an R package for microbiome data visualization and statistics. J. Open Sour. Softw. 6(63), 3201 (2021).","journal-title":"J. Open Sour. Softw."},{"key":"91734_CR38","first-page":"433","volume":"14","author":"AH Wu","year":"2022","unstructured":"Wu, A. H., Vigen, C., Tseng, C., Garcia, A. A. & Spicer, D. Effect of chemotherapy on the gut microbiome of breast cancer patients during the first year of treatment. Breast Cancer (Dove Med Press) 14, 433\u2013451 (2022).","journal-title":"Breast Cancer (Dove Med Press)"},{"issue":"24","key":"91734_CR39","doi-asserted-by":"publisher","first-page":"6200","DOI":"10.3390\/cancers13246200","volume":"13","author":"R Aarnoutse","year":"2021","unstructured":"Aarnoutse, R. et al. Intestinal microbiota in postmenopausal breast cancer patients and controls. Cancers (Basel) 13(24), 6200 (2021).","journal-title":"Cancers (Basel)"},{"key":"91734_CR40","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/djv147","author":"JJ Goedert","year":"2015","unstructured":"Goedert, J. J. et al. Investigation of the association between the fecal microbiota and breast cancer in postmenopausal women: a population-based case-control pilot study. J. Natl. Cancer Inst. https:\/\/doi.org\/10.1093\/jnci\/djv147 (2015).","journal-title":"J. Natl. Cancer Inst."},{"issue":"1","key":"91734_CR41","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1186\/s40168-018-0515-3","volume":"6","author":"J Zhu","year":"2018","unstructured":"Zhu, J. et al. Breast cancer in postmenopausal women is associated with an altered gut metagenome. Microbiome 6(1), 136 (2018).","journal-title":"Microbiome"},{"issue":"2","key":"91734_CR42","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1007\/s10549-020-05702-6","volume":"182","author":"AH Wu","year":"2020","unstructured":"Wu, A. H. et al. Gut microbiome associations with breast cancer risk factors and tumor characteristics: A pilot study. Breast Cancer Res. Treat. 182(2), 451\u2013463 (2020).","journal-title":"Breast Cancer Res. Treat."},{"issue":"11","key":"91734_CR43","doi-asserted-by":"publisher","first-page":"2712","DOI":"10.1002\/ijc.33473","volume":"148","author":"DA Byrd","year":"2021","unstructured":"Byrd, D. A. et al. Associations of fecal microbial profiles with breast cancer and nonmalignant breast disease in the Ghana Breast Health Study. Int. J. Cancer 148(11), 2712\u20132723 (2021).","journal-title":"Int. J. Cancer"},{"key":"91734_CR44","doi-asserted-by":"publisher","first-page":"117693432110575","DOI":"10.1177\/11769343211057573","volume":"17","author":"P Yang","year":"2021","unstructured":"Yang, P., Wang, Z., Peng, Q., Lian, W. & Chen, D. Comparison of the gut microbiota in patients with benign and malignant breast tumors: A pilot study. Evol. Bioinform. Online 17, 11769343211057572 (2021).","journal-title":"Evol. Bioinform. Online"},{"issue":"2","key":"91734_CR45","doi-asserted-by":"publisher","first-page":"217","DOI":"10.33073\/pjm-2022-019","volume":"71","author":"Z Ma","year":"2022","unstructured":"Ma, Z., Qu, M. & Wang, X. Analysis of gut microbiota in patients with breast cancer and benign breast lesions. Pol. J. Microbiol. 71(2), 217\u2013226 (2022).","journal-title":"Pol. J. Microbiol."},{"issue":"6","key":"91734_CR46","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1016\/j.chom.2024.05.009","volume":"32","author":"J de la Cuesta-Zuluaga","year":"2024","unstructured":"de la Cuesta-Zuluaga, J., Boldt, L. & Maier, L. Response, resistance, and recovery of gut bacteria to human-targeted drug exposure. Cell Host. Microbe 32(6), 786\u2013793 (2024).","journal-title":"Cell Host. Microbe"},{"issue":"13","key":"91734_CR47","doi-asserted-by":"publisher","first-page":"2916","DOI":"10.3390\/jcm10132916","volume":"10","author":"MPH Schreurs","year":"2021","unstructured":"Schreurs, M. P. H., De Vos van Steenwijk, P. J., Romano, A., Dieleman, S. & Werner, H. M. J. How the gut microbiome links to menopause and obesity, with possible implications for endometrial cancer development. J. Clin. Med. 10(13), 2916 (2021).","journal-title":"J. Clin. Med."},{"issue":"10","key":"91734_CR48","doi-asserted-by":"publisher","first-page":"2292","DOI":"10.3390\/molecules29102292","volume":"29","author":"J Wasiak","year":"2024","unstructured":"Wasiak, J. et al. Lactic acid bacteria-derived postbiotics as adjunctive agents in breast cancer treatment to boost the antineoplastic effect of a conventional therapeutic comprising tamoxifen and a new drug candidate: An aziridine-hydrazide hydrazone derivative. Molecules 29(10), 2292 (2024).","journal-title":"Molecules"},{"issue":"8","key":"91734_CR49","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1038\/nrc2683","volume":"9","author":"JM Hoskins","year":"2009","unstructured":"Hoskins, J. M., Carey, L. A. & McLeod, H. L. CYP2D6 and tamoxifen: DNA matters in breast cancer. Nat. Rev. Cancer 9(8), 576\u2013586 (2009).","journal-title":"Nat. Rev. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91734-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91734-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,7]],"date-time":"2025-03-07T01:05:35Z","timestamp":1741309535000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-91734-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,6]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["91734"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-91734-1","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,6]]},"assertion":[{"value":"13 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"LEH, JZ, and MLS have received research funding from Danone Global Research & Innovation Center, outside the submitted work. Additionally, MLS, RA, and JVG have received funding from Servier, and MLS from Illumina, all outside the submitted work. JVG has served as a consultant for Amgen, AstraZeneca, MSD, Pierre Fabre, and Servier, all outside the submitted work. JP has received research funding from Friesland Campina outside the submitted work. All other authors have no competing interests. All other authors have no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Medical Ethics Committee of azM\/UM and conducted in accordance with the Declaration of Helsinki and Good Clinical Practice guidelines. All patients provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"7874"}}